ABL Bio Inc.
298380.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.69T
Close$
Share Statistics
| Market cap | $2.69 Trillion |
|---|---|
| Enterprise Value | $2.60 Trillion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-703.38 |
| Beta | 0.23 |
| Outstanding Shares | 55,987,000 |
Return
| Return on Equity | -45.88% |
|---|---|
| Return on Assets | -28.74% |
| Return on Invested Capital | -48.46% |
Valuation & Multiples
| P/E Ratio | -33.26 |
|---|---|
| PEG | 24.28 |
| Price to Sales | 73.04 |
| Price to Book Ratio | 14.39 |
| Enterprise Value to Revenue | 75.97 |
| Enterprise Value to EBIT | -30.76 |
| Enterprise Value to Net Income | -34 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.48 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About ABL Bio Inc.
102 employees
CEO: Sang Hoon Lee ABL Bio Inc. is a biotechnology research company based in Seongnam, South Korea. The firm is dedicated to advancing therapeutic medications, primarily concentrating its efforts on treatments for immuno-oncology and neurodegenerative cond...